Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers

High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers
CDC on Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers
Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers in the news
Blogs on Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Timeline

Timeline
Start Date
Run-In Period
End Date
Status

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT------.

Study Description

Study Description
Study Type
Study Phase
Study Design
Allocation
Endpoint
Interventional Model
Masking
Study Details
Primary Purpose
Condition
Intervention
Study Arms
Population Size

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT-----.